Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
The Motley Fool10d
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
Furthermore, should the oral form of VK2735 actually be approved sometime ... As a proxy, Lilly's Mounjaro and Zepbound are on track for $14.7 billion in combined sales for 2024 -- essentially ...